In the absence of a submission from the holder of the marketing authorisation, atorvastatin/ezetimibe (Atozet®) cannot be endorsed for use within NHS Wales as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate in patients not appropriately controlled with a statin alone or in patients already treated with a statin and ezetimibe; and, as adjunctive therapy to diet for use in adults with homozygous familial hypercholesterolaemia (HoFH).